logo
Share SHARE
FONT-SIZE Plus   Neg

Auxilium Pharma Reports Positive Top-line Data From XIAFLEX Phase IIIb Trial

Auxilium Pharmaceuticals Inc. (AUXL) reported positive top-line data from its open-label phase IIIb study, assessing XIAFLEX for the treatment of adult Dupuytren's contracture patients with multiple palpable cords. The company enrolled 60 patients at 8 sites throughout the U.S. and Australia. During the third quarter of 2012, Auxilium expects to begin a larger study with XIAFLEX for the concurrent treatment of multiple palpable cords that, if successful, may allow the company to seek Food and Drug Administration approval and expansion of the Dupuytren's label.

Based on research by SDI Health, LLC estimating that 35% - 40% of annual Dupuytren's surgeries in the U.S. are performed to treat two or more cords concurrently, Auxilium is conducting these trials to seek a multicord indication for XIAFLEX from the FDA.

In this phase IIIb multicord trial, 60 patients received two concurrent injections of 0.58 mg of XIAFLEX per affected hand and efficacy was based on a single injection per contracted joint.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
PayPal has agreed to buy Xoom, a digital money transfer provider, for $890 million in cash. Following the announcement, Xoom shares jumped 22 percent in after-hours trade on the Nasdaq. Discount retailer Family Dollar Stores Inc., which is being acquired by rival Dollar Tree Inc., said Wednesday after the markets closed that its third quarter profit fell slightly from last year, due mainly to a higher effective tax rate. The company's quarterly earnings per share, excluding items, also came in below analysts' expectations. Diplomatic ties have been restored, so Cuba will surely see an influx of massive cruise ships and curious Americans.
comments powered by Disqus
Follow RTT